Kestrel Ophthalmics Limited 04246440 false 2024-01-01 2024-12-31 2024-12-31 The principal activity of the company is wholesale of pharmaceutical goods and of medical devices Digita Accounts Production Advanced 6.30.9574.0 true true true 04246440 2024-01-01 2024-12-31 04246440 2024-12-31 04246440 bus:OrdinaryShareClass1 2024-12-31 04246440 core:CurrentFinancialInstruments 2024-12-31 04246440 core:CurrentFinancialInstruments core:WithinOneYear 2024-12-31 04246440 core:Non-currentFinancialInstruments 2024-12-31 04246440 core:Non-currentFinancialInstruments core:AfterOneYear 2024-12-31 04246440 core:OtherResidualIntangibleAssets 2024-12-31 04246440 core:FurnitureFittingsToolsEquipment 2024-12-31 04246440 core:OtherPropertyPlantEquipment 2024-12-31 04246440 bus:SmallEntities 2024-01-01 2024-12-31 04246440 bus:Audited 2024-01-01 2024-12-31 04246440 bus:FullAccounts 2024-01-01 2024-12-31 04246440 bus:SmallCompaniesRegimeForAccounts 2024-01-01 2024-12-31 04246440 bus:RegisteredOffice 2024-01-01 2024-12-31 04246440 bus:CompanySecretary1 2024-01-01 2024-12-31 04246440 bus:Director2 2024-01-01 2024-12-31 04246440 bus:Director6 2024-01-01 2024-12-31 04246440 bus:Director7 2024-01-01 2024-12-31 04246440 bus:OrdinaryShareClass1 2024-01-01 2024-12-31 04246440 bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 04246440 core:LicencesFranchises 2024-01-01 2024-12-31 04246440 core:OtherResidualIntangibleAssets 2024-01-01 2024-12-31 04246440 core:PatentsTrademarksLicencesConcessionsSimilar 2024-01-01 2024-12-31 04246440 core:FurnitureFittings 2024-01-01 2024-12-31 04246440 core:FurnitureFittingsToolsEquipment 2024-01-01 2024-12-31 04246440 core:LeaseholdImprovements 2024-01-01 2024-12-31 04246440 core:OtherPropertyPlantEquipment 2024-01-01 2024-12-31 04246440 1 2024-01-01 2024-12-31 04246440 countries:England 2024-01-01 2024-12-31 04246440 2023-12-31 04246440 core:OtherResidualIntangibleAssets 2023-12-31 04246440 core:FurnitureFittingsToolsEquipment 2023-12-31 04246440 core:OtherPropertyPlantEquipment 2023-12-31 04246440 2023-01-01 2023-12-31 04246440 2023-12-31 04246440 bus:OrdinaryShareClass1 2023-12-31 04246440 core:CurrentFinancialInstruments 2023-12-31 04246440 core:CurrentFinancialInstruments core:WithinOneYear 2023-12-31 04246440 core:Non-currentFinancialInstruments 2023-12-31 04246440 core:Non-currentFinancialInstruments core:AfterOneYear 2023-12-31 04246440 core:OtherResidualIntangibleAssets 2023-12-31 04246440 core:FurnitureFittingsToolsEquipment 2023-12-31 04246440 core:OtherPropertyPlantEquipment 2023-12-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 04246440

Kestrel Ophthalmics Limited

Filleted Financial Statements

for the Year Ended 31 December 2024

 

Kestrel Ophthalmics Limited

Contents

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

3 to 8

 

Kestrel Ophthalmics Limited

Company Information

Directors

Mr J Boudet

Mr K C Oster

Mr Yves Brouquet-Laglaire

Company secretary

Ms M N Cavert

Registered office

9 Cabot Business Village
Holyrood Close
Poole
Dorset
BH17 7BA

Auditors

Hill Osborne Ltd
Registered Auditors & Chartered Accountants
2 Winchester Place
North Street
Poole
Dorset
BH15 1NX

 

Kestrel Ophthalmics Limited

(Registration number: 04246440)
Balance Sheet as at 31 December 2024

Note

2024
£

2023
£

Fixed assets

 

Intangible assets

4

82,887

117,084

Tangible assets

5

13,771

11,298

 

96,658

128,382

Current assets

 

Stocks

6

371,303

332,580

Debtors

7

498,973

550,804

Cash at bank and in hand

 

496

26,330

 

870,772

909,714

Creditors: Amounts falling due within one year

8

(753,324)

(747,885)

Net current assets

 

117,448

161,829

Total assets less current liabilities

 

214,106

290,211

Creditors: Amounts falling due after more than one year

8

-

(15,833)

Net assets

 

214,106

274,378

Capital and reserves

 

Called up share capital

10

100

100

Retained earnings

214,006

274,278

Shareholders' funds

 

214,106

274,378

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 25 November 2025 and signed on its behalf by:
 

.........................................
Mr J Boudet
Director

   

   
 

Kestrel Ophthalmics Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

1

General information

The company is a private company limited by share capital, incorporated in England.

The address of its registered office is:
9 Cabot Business Village
Holyrood Close
Poole
Dorset
BH17 7BA
England

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements were prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

The financial statements are prepared in sterling, which is the functional currency of the entity, and rounded to the nearest £1.

Going concern

The financial statements have been prepared on a going concern basis.

Turnover

Turnover represents amounts chargeable, net of value added tax, in respect of the sale of goods and services to customers.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

Tax

The tax expense represents the sum of the tax currently payable and deferred tax.

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

 

Kestrel Ophthalmics Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

2

Accounting policies (continued)

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Fixtures and fittings

4 years Straight line

Leasehold improvements

10 years Straight line

Other property, plant and equipment

5 years Straight line

Intangible assets - other

Intangible assets are stated in the statement of financial position at cost, less any subsequent accumulated amortisation.

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Intangible type

Useful life

Licensing distribution agreement

6 years straight line from the date of the first product distribution

Trademarks

6 years straight line

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

 

Kestrel Ophthalmics Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

2

Accounting policies (continued)

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Stocks

Stock is valued at the lower of cost and net realisable value, after due regard for obsolete and slow moving stocks. Net realisable value is based on selling price less anticipated costs to completion and selling costs.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Leases

Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 10 (2023 - 10).

 

Kestrel Ophthalmics Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

4

Intangible assets

Other intangible assets
 £

Total
£

Cost or valuation

At 1 January 2024

205,184

205,184

At 31 December 2024

205,184

205,184

Amortisation

At 1 January 2024

88,100

88,100

Amortisation charge

34,197

34,197

At 31 December 2024

122,297

122,297

Carrying amount

At 31 December 2024

82,887

82,887

At 31 December 2023

117,084

117,084

5

Tangible assets

Fixtures and fittings
 £

Plant and machinery
 £

Total
£

Cost or valuation

At 1 January 2024

167,450

149,057

316,507

Additions

7,459

-

7,459

At 31 December 2024

174,909

149,057

323,966

Depreciation

At 1 January 2024

164,430

140,779

305,209

Charge for the year

2,301

2,685

4,986

At 31 December 2024

166,731

143,464

310,195

Carrying amount

At 31 December 2024

8,178

5,593

13,771

At 31 December 2023

3,020

8,278

11,298

6

Stocks

2024
£

2023
£

Finished goods and goods for resale

371,303

332,580

 

Kestrel Ophthalmics Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

7

Debtors

2024
£

2023
£

Trade debtors

245,179

239,311

Amounts owed by group undertakings and undertakings in which the company has a participating interest

212,665

268,313

Other debtors

41,129

43,180

498,973

550,804

8

Creditors

Creditors: amounts falling due within one year

Note

2024
£

2023
£

Due within one year

 

Loans and borrowings

9

88,876

47,500

Trade creditors

 

502,055

502,882

Taxation and social security

 

83,781

113,274

Accruals and deferred income

 

68,855

74,908

Other creditors

 

9,757

9,321

 

753,324

747,885

Creditors: amounts falling due after more than one year

Note

2024
£

2023
£

Due after one year

 

Loans and borrowings

9

-

15,833

9

Loans and borrowings

2024
£

2023
£

Non-current loans and borrowings

Bank borrowings

-

15,833

2024
£

2023
£

Current loans and borrowings

Bank borrowings

15,834

47,500

Bank overdrafts

73,042

-

88,876

47,500

 

Kestrel Ophthalmics Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

9

Loans and borrowings (continued)

Bank security

The bank borrowings of the company are secured by a fixed and floating charge over the assets of the company.

10

Share capital

Allotted, called up and fully paid shares

 

2024

2023

 

No.

£

No.

£

Ordinary shares of £1 each

100

100

100

100

         

11

Financial commitments, guarantees and contingencies

Amounts not provided for in the balance sheet

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2024
 £

2023
 £

Total commitments

71,928

69,169

12

Related party transactions

The company has taken advantage of the exemption available in Section 33.1A of FRS 102 whereby it has not disclosed transactions with the parent company or any wholly owned subsidiary undertaking of the group.

13

Parent and ultimate parent undertaking

The company's immediate parent is Cutting Edge Sas, incorporated in France.

 The most senior parent entity producing publicly available financial statements is Cutting Edge Sas. These financial statements are available upon request from 770, Rue Alfred Nobel, Immeuble le Nobel, 34 000 Montpellier, France.

14

Audit report

As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006.

The auditor's report is unqualified.

Senior Statutory Auditor: Paul Francis FCA
Statutory Auditor: Hill Osborne Ltd
Date of audit report: 26 November 2025